Search Result

Results for "

Fc receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Apoptosis (5) BMX Kinase (1) Btk (3) CD3 (2) CD38 (1) EGFR (1) Endogenous Metabolite (1) FGFR (1) Insulin Receptor (1) Interleukin Related (1) PD-1/PD-L1 (2) TGF-β Receptor (1) TNF Receptor (3) Toll-like Receptor (TLR) (1) Wnt (1)
By Research Areas:	Cancer (18) Inflammation/Immunology (15) Metabolic Disease (5)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

507

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99489

Budigalimab ABBV 181; PR 1648817	PD-1/PD-L1	Cancer
Budigalimab (ABBV 181; PR 1648817) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) *receptor. Budigalimab is Fc mutated thus to reduce Fc receptor* interactions and limit effector function .

HY-P9954

Catumaxomab	CD3	Cancer
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .

HY-P99667

Ipafricept OMP-54F28; FZD8-Fc	Wnt	Cancer
Ipafricept (OMP-54F28; FZD8-Fc) is the first class of recombinant fusion proteins, consisting of the extracellular portion of the human fried-8 receptor fused to the Fc fragment of human IgG1 binding to the Wnt ligand. Ipafricept shows solid tumor inhibition activity, with well tolerance .

HY-N12840

Logmalicid B

Others Metabolic Disease

Logmalicid B is an iridoid glycoside compound that can be isolated from Cornus officinalis and can be used in diabetes research .

Logmalicid B	Others	Metabolic Disease
Logmalicid B is an iridoid glycoside compound that can be isolated from Cornus officinalis and can be used in diabetes research .

HY-145775

*hIgG-hFc receptor-IN-1*	Others	Inflammation/Immunology
hIgG–hFc receptor-IN-1 (comp 66) is a human immunoglobulin G–human neonatal Fc receptor (hIgG–hFcRn) protein-protein interaction inhibitor, with an IC₅₀ of 2 μM .

HY-P99930

Efruxifermin	FGFR	Metabolic Disease
Efruxifermin is an *Fc-FGF21* fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .

HY-P99692

Lenercept p55TNF-R:Ig; Ro 45-2081; TNFR55-IgG1	TNF Receptor	Inflammation/Immunology
Lenercept (Ro 45-2081) is a recombinant fusion protein that consists of the soluble *TNF-receptor* (p55) linked to the Fc portion of human IgG1 .

HY-P99487

Briobacept BR 3Fc	ADC Antibody	Inflammation/Immunology
Briobacept (BR 3FC) is a selective human monoclonal antibody targeting to BLyS (BAFF), induces B cells apoptosis. Briobacept is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept can be used in studies of rheumatoid arthritis (RA) .

HY-P9976A

Isatuximab (anti-CD38) 1 Publications Verification	CD38	Cancer
Isatuximab (anti-CD38) is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38.Isatuximab induces tumor cell killing via fragment crystallizable (Fc)-dependent or Fc-independent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) .

HY-147584

BTK-IN-14	Btk	Inflammation/Immunology Cancer
BTK-IN-14 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-14 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022057894A1, compound 1) .

HY-147581

BTK-IN-11	Btk	Inflammation/Immunology Cancer
BTK-IN-11 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-11 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022063101A1, compound Z2) .

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

HY-P99332

Visilizumab Anti-Human CD3E Recombinant Antibody; HuM291	Apoptosis	Inflammation/Immunology
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .

HY-109010

Poseltinib HM71224; LY3337641	Btk BMX Kinase Toll-like Receptor (TLR)	Metabolic Disease
Poseltinib (HM71224) is an orally active, selective, irreversible small molecule Bruton tyrosine kinase (BTK) inhibitor. With an IC₅₀ of 1.95 nM. Poseltinib effectively inhibits the signaling mediated by B cell receptors (BCR), Fc receptors (FcR), and Toll-like receptors (TLR). Poseltinib has anti-inflammatory activity and can be used in the research of rheumatoid arthritis .

HY-P990067

Evunzekibart ATOR-1017	TNF Receptor	Cancer
Evunzekibart (ATOR-1017) is an Fc-γ receptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.

HY-P9977

Amivantamab 1 Publications Verification JNJ-61186372	EGFR	Cancer
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .

HY-P99052

Tislelizumab 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 research. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer .

HY-P99470

Benufutamab GEN1029	TNF Receptor Apoptosis	Cancer
Benufutamab (GEN1029) is a *death receptor* 5 (DR5)**-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects .

HY-NP006

Protein A SPA	Endogenous Metabolite	Inflammation/Immunology
Protein A (SPA) is an immunoglobulin (Ig) binding protein that exists on the surface of bacteria and can be freely secreted into the extracellular environment. Protein A blocks opsonization and phagocytosis and induces B-cell death in vitro by binding to the Fc region of antibodies and the Fab region of B-cell receptors. Protein A has the ability to inhibit opsonization and phagocytosis in vitro .

HY-P99665

Insulin efsitora alfa LY-3209590	Insulin Receptor	Metabolic Disease
Insulin efsitora alfa (LY-3209590) is a selective agonist of *insulin receptor* (IR)**. Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes .

HY-P99590

Sotatercept ACE-011	TGF-β Receptor	Inflammation/Immunology Cancer
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .

HY-158316

BTL-MK	Others	Others
BTL-MK (Compound 19) an orally active antiallergic agent, that inhibits degranulation of mast cells with an IC₅₀ of 6.7 μM, through binding to the inhibitory receptor FcγRIIB. BTL-MK improves the metaboilic stability in human liver microsomes. BTL-MK ameliorates the allergic response in Ovalbumins (HY-W250978)-induced food allergy mice model. BTL-MK exhibits a good pharmacokinetic character with metabolic stability .

HY-13690

Mitotane 1 Publications Verification 2,4′-DDD; o,p'-DDD	Apoptosis	Cancer
Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .

HY-13690S1

Mitotane-13C6 2,4′-DDD-¹³C₆; o,p'-DDD-¹³C₆	Apoptosis	Cancer
Mitotane- ¹³C₆ is the ¹³C labeled Mitotane[1]. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions[2][3][4][5].

HY-13690S2

Mitotane-d8 2,4′-DDD-d₈; o,p'-DDD-d₈	Apoptosis	Cancer
Mitotane-d₈ is the deuterium labeled Mitotane[1]. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions[2][3][4][5].

HY-P99661

Inbakicept	Interleukin Related	Cancer
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .

Protein A SPA	Native Proteins
Protein A (SPA) is an immunoglobulin (Ig) binding protein that exists on the surface of bacteria and can be freely secreted into the extracellular environment. Protein A blocks opsonization and phagocytosis and induces B-cell death in vitro by binding to the Fc region of antibodies and the Fab region of B-cell receptors. Protein A has the ability to inhibit opsonization and phagocytosis in vitro .

ACE-031 Myostatin inhibitory peptide 7	Peptides	Others
ACE-031 (Myostatin inhibitory peptide 7) is a recombinant protein comprised of activin receptor type IIB (ActRIIB) linked to the Fc region of human immunoglobulin IgG1. ACE-031 exhibits inhibitory activity against myostatin and other negative regulators of muscle mass, promotes muscle growth .

Cat. No.	Product Name	Target	Research Area

HY-P99381

XmAb 5592	Inhibitory Antibodies	Cancer
XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) .

HY-P99446

Atacicept TACI-Ig; TACI-Fc 5	Inhibitory Antibodies	Inflammation/Immunology
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .

HY-P99037

Nipocalimab M281	Inhibitory Antibodies	Inflammation/Immunology
Nipocalimab (M281) is a fully human, recombinant, aglycosylated IgG1 monoclonal antibody. Nipocalimab is a human deglycosylated IgG1 anti-FcRn monoclonal antibody that binds with picomolar affinity to Fc receptor (FcRn) at both endosomal pH 6.0 and extracellular pH 7.6 .

HY-P99489

Budigalimab ABBV 181; PR 1648817	PD-1/PD-L1	Cancer
Budigalimab (ABBV 181; PR 1648817) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) *receptor. Budigalimab is Fc mutated thus to reduce Fc receptor* interactions and limit effector function .

HY-P99529

Valziflocept BAX1810; TAK-752	Inhibitory Antibodies	Inflammation/Immunology
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE) .

HY-P9954

Catumaxomab	CD3	Cancer
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .

HY-P99667

Ipafricept OMP-54F28; FZD8-Fc	Wnt	Cancer
Ipafricept (OMP-54F28; FZD8-Fc) is the first class of recombinant fusion proteins, consisting of the extracellular portion of the human fried-8 receptor fused to the Fc fragment of human IgG1 binding to the Wnt ligand. Ipafricept shows solid tumor inhibition activity, with well tolerance .

HY-P99930

Efruxifermin	FGFR	Metabolic Disease
Efruxifermin is an *Fc-FGF21* fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .

HY-P99932

Eftansomatropin alfa	Inhibitory Antibodies	Others
Eftansomatropin alfa is an antibody targeting the growth hormone receptor (GSH). Eftansomatropin alfa is a fusion protein of GH1 and IGHG4 Fc .

HY-P99692

Lenercept p55TNF-R:Ig; Ro 45-2081; TNFR55-IgG1	TNF Receptor	Inflammation/Immunology
Lenercept (Ro 45-2081) is a recombinant fusion protein that consists of the soluble *TNF-receptor* (p55) linked to the Fc portion of human IgG1 .

HY-P99487

Briobacept BR 3Fc	ADC Antibody	Inflammation/Immunology
Briobacept (BR 3FC) is a selective human monoclonal antibody targeting to BLyS (BAFF), induces B cells apoptosis. Briobacept is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept can be used in studies of rheumatoid arthritis (RA) .

HY-P9976A

Isatuximab (anti-CD38) 1 Publications Verification	CD38	Cancer
Isatuximab (anti-CD38) is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38.Isatuximab induces tumor cell killing via fragment crystallizable (Fc)-dependent or Fc-independent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) .

HY-P9979

Rozanolixizumab UCB7665	Inhibitory Antibodies	Inflammation/Immunology
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .

HY-P9950

Omalizumab 1 Publications Verification Olizumab; rhuMab-E25	Inhibitory Antibodies	Inflammation/Immunology Cancer
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a K_D of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a K_D of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research .

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

HY-P99332

Visilizumab Anti-Human CD3E Recombinant Antibody; HuM291	Apoptosis	Inflammation/Immunology
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .

HY-P990067

Evunzekibart ATOR-1017	TNF Receptor	Cancer
Evunzekibart (ATOR-1017) is an Fc-γ receptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.

HY-P9977

Amivantamab 1 Publications Verification JNJ-61186372	EGFR	Cancer
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .

HY-P99052

Tislelizumab 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 research. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer .

HY-P99470

Benufutamab GEN1029	TNF Receptor Apoptosis	Cancer
Benufutamab (GEN1029) is a *death receptor* 5 (DR5)**-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects .

HY-P99008

Atibuclimab 1 Publications Verification	Inhibitory Antibodies	Inflammation/Immunology
Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis . Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist .

HY-P99665

Insulin efsitora alfa LY-3209590	Insulin Receptor	Metabolic Disease
Insulin efsitora alfa (LY-3209590) is a selective agonist of *insulin receptor* (IR)**. Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes .

HY-P99590

Sotatercept ACE-011	TGF-β Receptor	Inflammation/Immunology Cancer
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .

HY-P990076

Lorukafusp alfa 14.18 mAb; hu14.18-IL2; EMD 273063	Inhibitory Antibodies	Cancer
Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity .

HY-P99661

Inbakicept	Interleukin Related	Cancer
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N12840

Logmalicid B	Structural Classification Iridoids Cornaceae Cornus officinalis Sieb. et Zucc. Terpenoids Source classification Plants	Others
Logmalicid B is an iridoid glycoside compound that can be isolated from Cornus officinalis and can be used in diabetes research .

Cat. No.	Product Name	Chemical Structure

HY-13690S1

Mitotane-13C6

Mitotane- ¹³C₆ is the ¹³C labeled Mitotane[1]. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions[2][3][4][5].

HY-13690S2

Mitotane-d8

Mitotane-d₈ is the deuterium labeled Mitotane[1]. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions[2][3][4][5].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81527

	FCRL4 Antibody (YA1272) FcRL4; FcRH4, IFGP2, IRTA1; Fc receptor-like protein 4; CD307d; FcR-like protein 4; FcRL4; Fc receptor homolog 4 (FcRH4); IFGP family protein 2 (hIFGP2); Immune receptor translocation-associated protein 1	IHC-P	Human

HY-P82215

CD89 Antibody (YA1960)

FcAR; CD89; Immunoglobulin alpha Fc receptor; IgA Fc receptor; CD89
WB, IHC-P, ICC/IF, IP, FC Human

HY-P83505

	CD32 Antibody (YA3250) FcGR2A; CD32; FcG2; FcGR2A1; IGFR2; Low affinity immunoglobulin gamma Fc region receptor II-a; IgG Fc receptor II-a; CDw32; Fc-gamma RII-a; Fc-gamma-RIIa; FcRII-a; CD32	WB, IHC-P	Human

HY-P81202

	CD16 Antibody FcG3A_HUMAN; Low affinity immunoglobulin gamma Fc region receptor III-A; CD16a antigen; Fc-gamma RIII-alpha; Fc-gamma RIII; Fc-gamma RIIIa; FcRIII; FcRIIIa; FcR-10; IgG Fc receptor III-2; CD_antigen: D16a; FcGR3A; CD16A; FcG3; FcGR3; IGFR3.	WB, ELISA, IHC-P, IHC-F, FC, ICC/IF	Human, Mouse, Rat
	CD16 Antibody is an unconjugated, approximately 27 kDa, rabbit-derived, anti-CD16 polyclonal antibody. CD16 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, rat, and predicted: pig, cow, rabbit, sheep background without labeling.

HY-P81870

CD32B Antibody (YA1615)

Fc fragment of IgG; low affinity IIb; receptor (CD32); CD32; FcG2; CD32B; FcGR2; IGFR2
WB, IHC-P Human, Rat

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks